Literature DB >> 28957646

A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1.

Dean E McNulty1, William G Bonnette1, Hongwei Qi1, Liping Wang1, Thau F Ho1, Anna Waszkiewicz1, Lorena A Kallal1, Raman P Nagarajan1, Melissa Stern1, Amy M Quinn1, Caretha L Creasy1, Dai-Shi Su1, Alan P Graves1, Roland S Annan1, Sharon M Sweitzer1, Marc A Holbert1.   

Abstract

A persistent problem in early small-molecule drug discovery is the frequent lack of rank-order correlation between biochemical potencies derived from initial screens using purified proteins and the diminished potency and efficacy observed in subsequent disease-relevant cellular phenotypic assays. The introduction of the cellular thermal shift assay (CETSA) has bridged this gap by enabling assessment of drug target engagement directly in live cells based on ligand-induced changes in protein thermal stability. Initial success in applying CETSA across multiple drug target classes motivated our investigation into replacing the low-throughput, manually intensive Western blot readout with a quantitative, automated higher-throughput assay that would provide sufficient capacity to use CETSA as a primary hit qualification strategy. We introduce a high-throughput dose-response cellular thermal shift assay (HTDR-CETSA), a single-pot homogenous assay adapted for high-density microtiter plate format. The assay features titratable BacMam expression of full-length target proteins fused to the DiscoverX 42 amino acid ePL tag in HeLa suspension cells, facilitating enzyme fragment complementation-based chemiluminescent quantification of ligand-stabilized soluble protein. This simplified format can accommodate determination of full-dose CETSA curves for hundreds of individual compounds/analyst/day in replicates. HTDR-CETSA data generated for substrate site and alternate binding mode inhibitors of the histone-lysine N-methyltransferase SMYD3 in HeLa suspension cells demonstrate excellent correlation with rank-order potencies observed in cellular mechanistic assays and direct translation to target engagement of endogenous Smyd3 in cancer-relevant cell lines. We envision this workflow to be generically applicable to HTDR-CETSA screening spanning a wide variety of soluble intracellular protein target classes.

Entities:  

Keywords:  cell-based assays; epigenetics; ligand binding; pharmacology; phenotypic drug discovery; receptor binding

Mesh:

Substances:

Year:  2017        PMID: 28957646     DOI: 10.1177/2472555217732014

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  12 in total

1.  Importance of Quantifying Drug-Target Engagement in Cells.

Authors:  Jakub Stefaniak; Kilian V M Huber
Journal:  ACS Med Chem Lett       Date:  2020-03-06       Impact factor: 4.345

2.  Screening for Small-Molecule Inhibitors of Histone Methyltransferases.

Authors:  Nico Cantone; Richard T Cummings; Patrick Trojer
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Why 90% of clinical drug development fails and how to improve it?

Authors:  Duxin Sun; Wei Gao; Hongxiang Hu; Simon Zhou
Journal:  Acta Pharm Sin B       Date:  2022-02-11       Impact factor: 14.903

4.  Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors.

Authors:  Lester J Lambert; Celeste Romero; Douglas J Sheffler; Maria Celeridad; Nicholas D P Cosford; Lutz Tautz
Journal:  J Vis Exp       Date:  2020-07-17       Impact factor: 1.355

5.  A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.

Authors:  Celeste Romero; Lester J Lambert; Douglas J Sheffler; Laurent J S De Backer; Dhanya Raveendra-Panickar; Maria Celeridad; Stefan Grotegut; Socorro Rodiles; John Holleran; Eduard Sergienko; Elena B Pasquale; Nicholas D P Cosford; Lutz Tautz
Journal:  J Biol Chem       Date:  2020-01-17       Impact factor: 5.157

6.  Identification of Small-Molecule Inhibitors of Human Inositol Hexakisphosphate Kinases by High-Throughput Screening.

Authors:  Gangling Liao; Wenjuan Ye; Tyler Heitmann; Glen Ernst; Michael DePasquale; Laiyi Xu; Michael Wormald; Xin Hu; Marc Ferrer; Robert K Harmel; Dorothea Fiedler; James Barrow; Huijun Wei
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-03

7.  Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1.

Authors:  Joseph Shaw; Ian Dale; Paul Hemsley; Lindsey Leach; Nancy Dekki; Jonathan P Orme; Verity Talbot; Ana J Narvaez; Michal Bista; Daniel Martinez Molina; Michael Dabrowski; Martin J Main; Davide Gianni
Journal:  SLAS Discov       Date:  2018-12-13       Impact factor: 3.341

8.  The 2020 SLAS Discovery Top 10: Advancing the Science of Drug Discovery.

Authors:  Robert M Campbell
Journal:  SLAS Discov       Date:  2021-02       Impact factor: 3.341

9.  A high content, high throughput cellular thermal stability assay for measuring drug-target engagement in living cells.

Authors:  Andrew J Massey
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

10.  A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase.

Authors:  Natalia J Martinez; Rosita R Asawa; Matthew G Cyr; Alexey Zakharov; Daniel J Urban; Jacob S Roth; Eric Wallgren; Carleen Klumpp-Thomas; Nathan P Coussens; Ganesha Rai; Shyh-Ming Yang; Matthew D Hall; Juan J Marugan; Anton Simeonov; Mark J Henderson
Journal:  Sci Rep       Date:  2018-06-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.